See how your reported results read as versioned evidence records β linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to review claims
Explore by Goal
"The universe is not only queerer than we suppose, but queerer than we can suppose."
- J.B.S. Haldane
Quick Explanation
Copied
Yu Feng β scientific signal check
Across the provided record, the strongest evidence chunks are: (1) in-vivo/in-vitro mechanistic biology for TCM-derived formulas in fibrosis/allergy, and (2) computational-method papers with explicit model-training/evaluation descriptions (e.g., SAXS/NMR-constrained structure reconstruction), .
However, the provided author bibliometrics appear inconsistent (name-collision risk), so you should verify that all cited papers truly share the same βYu Fengβ identity before drawing any career-level conclusions.
Long Explanation
Author Review (Science & Evidence): Yu Feng
Date context: April 18, 2026. This review is grounded only in the research items you provided (raw-extract summaries + DOIs/metadata). Where identity/origin is ambiguous, I explicitly flag uncertainty.
1) What the provided evidence actually supports
Mechanistic biology (TCM/immune/hepatic fibrosis context) is represented by rat-model and immune-model studies, where the record includes dosing, model description, and multiple readouts (histology/markers/gene expression or immune assays). Example: hepatic fibrosis prevention with Yu Ping Feng San fractioned polysaccharide (YPF-P) in a CCl4 rat model.
Network/omics & target-mechanism computation is represented by TCM network pharmacology work. Example: Yu Ping Feng decoction target-pathway network analysis.
High-constraint computational structural biology appears in the protein conformational reconstruction paper that explicitly discusses training data (NMR ensembles), evaluation targets (40 systems), and reported metric changes for SAXS loss and ensemble diversity.
Cell-type-specific systems biology appears in a brain metabolomics atlas study with FACS-sorted transgenic mouse cell populations, multi-platform metabolomics (targeted and untargeted), RNA-seq integration, and an explicit data resource link.
The bibliometrics block you supplied includes an OpenAlex βmatchesβ list that does not correspond to the name βYu Fengβ (it shows other peopleβs author profiles such as βZhenan Baoβ, βK. F. Chenβ, etc.). This creates a major name-collision / misattribution risk and prevents me from confidently tying the provided h-index/citation counts to the same individual across all referenced papers.
Because of that, I treat the paper-level evidence below as paper-claims evidence, not automatically as βthis is Yu Fengβs personal research trajectoryβ unless the paperβs authorship is explicitly confirmed in the source you intended.
3) Visual evidence from one included raw-extract dataset (hepatic fibrosis)
The record includes a semi-quantitative fibrosis scoring distribution (categories 0β4) across treatment groups. I visualize the reported Average ratio Β± SD and the category counts to check whether the response is dose-dependent and monotonic.
Interpretation with epistemic humility: the extracted data are semi-quantitative distributions, so apparent monotonic trends should be treated cautiously (possible scoring variability, limited sample sizes, and single-model limitations). The underlying paper reports dose-dependent improvement for YPF-P.
4) Paper-level critique across the provided set (what looks strong vs weak)
4.1 Stronger-evidence patterns
Explicit experimental perturbation + mechanistic readouts appear in some biology papers (e.g., cGAS inhibition experiments include enzymatic inhibition logic, multi-level readouts, and cross-species model use).
Method papers with transparent training/evaluation show stronger reproducibility potential than purely narrative computational studies. Example: AlphaSAXS includes training data description, target list, and multiple evaluation metrics.
Omics atlas-style work provides concrete resources and includes multimodal measurement + public data links (e.g., metabolismocean).
4.2 Likely blind spots / weakness modes
Name/identity ambiguity (already discussed) means bibliometrics may not map to the same individual. This is the dominant epistemic risk in this dataset.
Translation risk in animal models: several included studies use rodents/mice/limited cell types, so human generalization remains uncertain by default (even if directionality is compelling). Example hepatic fibrosis in rats.
Model-system overreach in cross-species βadaptive isoformβ claims: bear-specific thermogenic TMEM41B isoform work relies on heterologous expression/indirect correlations and cross-species inference.
Computational prediction vs experimental validation gap: network pharmacology/target-prediction frameworks can produce plausible hypotheses but require wet-lab confirmation of binding/causality (this is a methodological limitation category, not a criticism of any one result). Example YaTCM and network-pharmacology style work.
Omics statistical multiplicity / confounding: large biobank proteomics studies derive subtypes from complex matrices; even with adjustments, unmeasured confounding and validation needs remain crucial.
5) What I cannot conclude from this dataset
I cannot reliably compute or interpret βYu Fengβsβ real h-index/citation metrics because the provided OpenAlex matching block appears inconsistent (name collision / wrong profile risk).
I cannot rank βbest paperβ authorship contribution (first/last/senior/consortium role) because the provided metadata does not include author-order details for the included DOIs.
I cannot assess reproducibility beyond what each provided abstract-extract reports about code/data availability and experimental design.
6) Confidence & error bars on this review
Confidence is limited by (a) the name-collision risk in bibliometrics, (b) the fact that many included items span different biological and computational domains, and (c) the dataset being an extracted set of paper summaries rather than a complete publication list.
Feedback:
Updated: April 19, 2026
BGPT Author Review
Scientific Quality
40%
The provided evidence spans multiple unrelated domains (TCM/immune biology, fungal taxonomy, neuroimmunometabolism, protein generative modeling, plant-pathogen biology), which could reflect breadth or could reflect name-collision/misattribution. Several included studies appear methodologically serious (explicit datasets, multi-readout experiments, and for some computational work, transparent training/evaluation), but the biggest red flag is that the supplied bibliometrics/openalex mapping does not clearly correspond to βYu Feng,β preventing reliable attribution and making it impossible to judge the authorβs true scientific contribution quality consistently.
Communication Quality
60%
The summaries you provided are relatively structured and include methods/readouts, suggesting clear scientific communication in the original works. However, because this review is based on extracted snippets and not the full author writing, I cannot credit βYu Fengβ specifically for writing quality; also the cross-domain spread makes narrative cohesion hard to assess.
Author Novelty
50%
Some items plausibly include novelty (e.g., SAXS/NMR constrained protein ensemble reconstruction; cell-type metabolome atlases; integrative microglia/splicing mechanistic cascade). But given identity ambiguity and domain-mixing, I cannot confidently quantify βYu Fengβsβ novelty across a coherent research program.
Scientific Rigor
50%
Several excerpts include good rigor indicators: perturbation/controls, multi-modal measurements, public data/code links, and explicit evaluation metrics. Yet many biology items rely on animal models and require translation cautions; computational/omics items likely need independent external validation; and the largest rigor limitation here is evidence attribution uncertainty to the correct Yu Feng identity.
It extracts the fibrosis category-count matrix and average-ratio uncertainties from your provided YPF-P dataset, then recomputes dose-response monotonicity scores and confidence intervals using ordinal models.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The simplistic claim that βTCM formulas work via one dominant targetβ is less supported by the provided network pharmacology framing, which treats effects as multi-component/multi-target systems and thus implies distributed mechanisms rather than a single dominant node.
A blanket generalization that cross-species isoform differences always map to the same biochemical mechanism in heterologous expression systems is weakened by the explicit reliance on inference + overexpression/heterologous models in the bear TMEM41B work.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Analysis 
Hypothesis Graveyard
Discussion